Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0

作者：

Grunwald, Viktor ^{[1
,2
]}

Powles, Thomas ^{[3
,4
]}

Eto, Masatoshi ^{[5
]}

Kopyltsov, Evgeny ^{[6
]}

Rha, Sun Young ^{[7
]}

Porta, Camillo ^{[8
]}

Motzer, Robert ^{[9
]}

Hutson, Thomas E. ^{[10
]}

Mendez-Vidal, Maria Jose ^{[11
]}

Hong, Sung-Hoo ^{[12
]}

Winquist, Eric ^{[13
]}

Goh, Jeffrey C. ^{[14
,15
]}

Maroto, Pablo ^{[16
]}

Buchler, Tomas ^{[17
,18
]}

Takagi, Toshio ^{[19
]}

Burgents, Joseph E. ^{[20
]}

Perini, Rodolfo ^{[21
]}

He, Cixin ^{[22
]}

Okpara, Chinyere E. ^{[23
]}

McKenzie, Jodi ^{[24
]}

Choueiri, Toni K. ^{[25
]}

机构：

[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany

[2] Univ Hosp Essen, Clin Urol, Essen, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] Queen Mary Univ London, Royal Free Hosp, London, England

[5] Kyushu Univ, Dept Urol, Fukuoka, Japan

[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia

[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea

[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Texas Oncol, Med Oncol, Dallas, TX USA

[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain

[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea

[13] Univ Western Ontario, Dept Oncol, London, ON, Canada

[14] ICON Res, South Brisbane, Qld, Australia

[15] Univ Queensland, St Lucia, Qld, Australia

[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic

[18] Thomayer Univ Hosp, Prague, Czech Republic

[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[21] Merck & Co Inc, Clin Res, Rahway, NJ USA

[22] Eisai Inc, Biostat, Nutley, NJ USA

[23] Eisai Ltd, Clin Res, Hatfield, England

[24] Eisai Inc, Clin Res, Nutley, NJ USA

[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 13卷

关键词：

renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;

D O I：

10.3389/fonc.2023.1343027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[21] Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
Motzer, Robert
George, Saby
Merchan, Jaime R.
Hutson, Thomas E.
Song, Xun
Perini, Rodolfo F.
Xie, Ran
Bapat, Urmi
Ebaid, Basant
Puente, Javier
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 121 - 122
[22] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
Ged, Yasser
Lee, Chung-Han
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
[23] Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
Motzer, Robert
George, Saby
Merchan, Jaime R.
Hutson, Thomas E.
Song, Xun
Perini, Rodolfo F.
Xie, Ran
Bapat, Urmi
Puente, Javier
[J]. ONCOLOGIST, 2023, 28 (06): : 501 - 509
[24] Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
Grunwald, Viktor
Motzer, Robert J.
Keizman, Daniel
Bedke, Jens
Schmidinger, Manuela
Staehler, Michael D.
Matveev, Vsevolod B.
George, Saby
Hutson, Thomas E.
Vaishampayan, Ulka N.
Merchan, Jaime R.
Eto, Masatoshi
Rha, Sun Young
Waddell, Tom
Sabbatini, Roberto
Barthelemy, Philippe
Burgents, Joseph E.
Ren, Min
Brown, Ian
Choueiri, Toni K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[25] Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Rha, Sun Young
Choueiri, Toni K.
Matveev, Vsevolod B.
Alyasova, Anna
Hong, Sung-Hoo
Gordoa, Teresa Alonso
Gurney, Howard
Bjarnason, Georg A.
Buchler, Tomas
Pedrazzoli, Paolo
Takagi, Toshio
Park, Se Hoon
Lee, Jae-Lyun
Perini, Rodolfo F.
He, Cixin
McKenzie, Jodi A.
Eto, Masatoshi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[26] A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)
Hutson, Thomas E.
Michaelson, M. Dror
Kuzel, Timothy M.
Agarwal, Neeraj
Molina, Ana M.
Hsieh, James J.
Vaishampayan, Ulka N.
Xie, Sharon
Bapat, Urmi
Jain, Rohit K.
Fishman, Mayer N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[27] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Choueiri, Toni K.
Eto, Masatoshi
Motzer, Robert
De Giorgi, Ugo
Buchler, Tomas
Basappa, Naveen S.
Mendez-Vidal, Maria Jose
Tjulandin, Sergei
Park, Se Hoon
Melichar, Bohuslav
Hutson, Thomas
Alemany, Carlos
McGregor, Bradley
Powles, Thomas
Gruenwald, Viktor
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Staehler, Michael
Merchan, Jaime R.
Xie, Ran
Perini, Rodolfo F.
Mody, Kalgi
McKenzie, Jodi
Porta, Camillo
[J]. LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
[28] A Phase IB/II Trial of Lenvatinib plus Pembrolizumab in Patients With Renal Cell Carcinoma
Lee, Chung-Han
Makker, Vicky
Rasco, Drew
Taylor, Matthew
Dutcus, Corina
Shumaker, Robert
Schmidt, Emmett
Stepan, Daniel E.
Li, Di
Young, Louise
Motzer, Robert
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 153 - 153
[29] Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
Gruenwald, V
Hutson, T.
Choueiri, T. K.
Motzer, R.
Rha, S. Y.
Alyasova, A.
Merchan, J.
Gurney, H.
Peer, A.
Takagi, T.
Porta, C.
Powles, T.
De Giorgi, U.
Vaishampayan, U.
Schmidinger, M.
Glen, H.
Rodriguez-Lopez, K.
Xing, D.
Dutta, L.
Eto, M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 275
[30] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
Haro-Silerio, Jaime Ivan
Johns, Andrew
Moussa, Mohammad Jad
Wang, Mindy
Wang, Emily
Kovitz, Craig A.
Campbell, Matthew T.
Jonasch, Eric
Shah, Amishi Yogesh
Tannir, Nizar M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433

← 1 2 3 4 5 →